Management
Kristina Torfgård
Chief Executive Officer since 2019
Kristina Torfgård has more than 25 years of experience in drug development from leading roles in the pharmaceutical and biopharma industry. She has previously worked at AstraZeneca with research and development in both early and late phase and has been globally responsible for marketed products. Kristina has also worked at the biopharma company Albireo AB/Pharma Inc, as VP Clinical & Regulatory Affairs and VP Global Project Head and was engaged in building the company.
Shareholdings and warrants:
4 000 shares
Warrants granting acquisition rights to:
53 000 shares (2020/2023, incentive program)
2 000 shares (TO2 2020/2022 program)
Education: MSc Pharmacy, PhD in Clinical Pharmacology
Other assignments: –
Anders Sandberg
Chief Scientific Officer since 2015
Anders is one of Alzinova’s co-founders and was also CEO of the Company during a transitional period. He has extensive experience in protein research with an emphasis on neurotoxic peptide devices. Anders has since 2007 worked with the ALZ-101 and ALZ-201 projects as its main occupation, and as chief operating officer has run much of the Company’s operations since it was founded in 2011. He is also a co-inventor of Alzinova’s AβCC technology and has been a deputy board member since 2011.
Shareholdings and warrants:
185 193 shares
Warrants granting acquisition rights to:
10 500 shares (2020/2023, incentive program)
96 596 shares (TO2 2020/2022 program)
Education: PhD in Chemistry
Other assignments: –
Håkan Skogström
Chief Financial Officer since 2020
Håkan has 20 years of experience from leading finance positions in the shipping industry. He has previously worked as CFO and CEO at a privately owned Swedish shipping company with international operations where he has been involved in building the company. Since the beginning of 2020 Håkan works as CFO for Safe at Sea AB. Håkan also works as financial consultant for small and medium-sized companies.
Shareholdings and warrants:
4 000 shares
Warrants granting acquisition rights to:
21 000 shares (2020/2023, incentive program)
2 000 shares (TO2 2020/2022 program)
Education: BSc Business and Economics, Small business management
Other assignments: CFO, Safe at Sea AB (publ)
Anders Bylock
Chief Medical Officer since 2019
Anders has more than 25 years of experience in drug development in both preclinical and phase I-IV clinical studies, as well as registration work on intra-EU approved medicines. He has worked at MSD Sweden, held leading positions at AstraZeneca and as Senior Global Director at Boehringer Ingelheim GmbH & Co KG in Germany, medically leading a large number of cardiovascular projects at various stages.
Shareholdings and warrants: –
Education: Licensed Physician, specialist in thoracic surgery. Associate Professor and Doctor of Medicine.
Other assignments: CMO, Aptahem AB (publ)
Ingela Nylander
Development Project Director since 2019
Ingela has more than 25 years of experience as a project leader in the pharmaceutical and biotech industry. Ingela has worked in all phases of drug development up to regulatory approval and market introduction. She spent 20 years at AstraZeneca, and thereafter co-founded Captario, a company that develops a strategic decision support systems for the pharmaceutical industry. Ingela has also worked as a senior consultant and advisor supporting small pharmaceutical and medical device companies.
Education: MSc Chemical Engineering, Certified Project Manager
Other assignments: Senior Advisor, MC Incubator
Shareholdings and warrants:
Warrants granting acquisition rights to:
10 500 shares (2020/2023, incentive program)